Streamlining Entyvio Prior Authorization for Dermatology Practices

Entyvio's Clinical Context and Prior Authorization Landscape

Entyvio, an integrin receptor antagonist, is a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans, primarily for its indications in ulcerative colitis and Crohn's disease. While dermatologists may consult on systemic manifestations of IBD, Entyvio is not typically a primary biologic for common dermatological conditions like psoriasis, atopic dermatitis, or hidradenitis suppurativa, which are addressed by other classes of biologics as outlined in major clinical guidelines. Understanding its specific clinical pathway is crucial for accurate PA submissions.

Dermatology Prior Authorization: A Focus on Biologics and Specialty Drugs

Dermatology practices frequently encounter prior authorization requirements for a range of high-cost biologics and specialty drugs. These include TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, and JAK inhibitors used for conditions such as psoriasis and psoriatic arthritis, as well as biologics for atopic dermatitis and hidradenitis suppurativa. The complexity is further compounded by procedures like Mohs micrographic surgery, which often trigger PA based on site and tumor characteristics.

Key Documentation for Biologic Prior Authorization in Dermatology

• Diagnosis confirmation with severity scores (e.g., PASI/BSA for psoriasis, EASI/SCORAD for atopic dermatitis).
• Documentation of prior topical therapy trials and, where applicable, phototherapy trials.
• Evidence of prior conventional systemic therapy trials (e.g., methotrexate, cyclosporine) for psoriasis/PsA biologics.
• Pre-biologic screenings for TB and hepatitis.
• Conformance to age-specific or other indication criteria (e.g., Dupixent age-specific indications).

Navigating Step Therapy and Clinical Guidelines for Dermatologic Biologics

Payer policies for dermatologic biologics often mandate strict adherence to step therapy protocols, frequently aligning with AAD Clinical Guidelines and NCCN for skin cancers. Common PA denial reasons include insufficient documentation of failed conventional therapies (topicals, phototherapy, methotrexate), lack of biosimilar substitution attempts for TNF inhibitors, and inadequate disease severity scores. Klivira's platform incorporates guideline-aware logic to help ensure submissions meet these complex requirements.

Klivira's Solution for Complex Biologic PAs in Dermatology

Klivira's prior authorization automation platform is engineered to address the specific workflow constraints of dermatology practices. This includes managing periodic re-authorization cycles for chronic biologic treatments, distinguishing between medical and pharmacy benefit routing for self-injection versus clinic infusion, and validating against appropriate use criteria for procedures like Mohs surgery. By integrating with EMRs and payer portals, Klivira streamlines the entire PA lifecycle, from initial submission to appeals.

Streamlining Dermatology PA Workflows with Klivira

• Automated validation against AAD-guideline-aware step-therapy logic for psoriasis and atopic dermatitis biologics.
• Efficient management of periodic re-authorization workflows for chronic biologic therapies.
• Accurate routing for medical-vs-pharmacy benefit claims based on administration method.
• Validation support for Mohs surgery against appropriate use criteria.
• Integration with EMRs to pull necessary clinical documentation for submission.